Journal ArticleDOI
Anti-cancer drugs
Reads0
Chats0
About:
This article is published in Current Pharmaceutical Design.The article was published on 2005-03-31. It has received 882 citations till now. The article focuses on the topics: Introductory Journal Article.read more
Citations
More filters
Journal ArticleDOI
Clinical meta-analyses of targeted therapies in adenocarcinoma
Emilio Bria,Maria Bonomi,Sara Pilotto,Francesco Massari,Silvia Novello,Matteo Giaj Levra,Giampaolo Tortora,Giorgio V. Scagliotti +7 more
TL;DR: The current review attempts to put in the context of the clinical data of targeted agents for lung cancer all the pros and cons of the meta-analytic process published to date, and critically analyze all the potential perspectives which this methodology may add for both current practice and forthcoming research.
Journal ArticleDOI
Effect of transannular interaction on the redox-potentials in a series of bicyclic quinones
TL;DR: First redox-potentials of substituted bicyclic quinones correlate with their calculated LUMO energies and the energies of reduction and are weighted significantly on the non-quinone part of the bicyclic system.
Antitumor Activity of Tetra-Substituted Zinc Phthalocyanines Containing 4(3H)-Quinazolinone Derivatives
TL;DR: Series of tetra-substituted zinc(II)phthalocyanines bearing four 4(3H) quinazolinone ring system units (qz)4ZnPcs 4a-c showed promising anticancer activity against the tested human cancer cell lines.
Journal ArticleDOI
Nitric oxide release by N-(2-chloroethyl)-N-nitrosoureas: a rarely discussed mechanistic path towards their anticancer activity
TL;DR: Initial studies of the cytotoxicity against two different cancer cell lines show that they are quite efficient even under hypoxic conditions, compared to the clinical compound BCNU, based on the results on human breast (MCF-7) and lung (A549) adeno carcinoma cell lines.
Journal ArticleDOI
Detecting role of apoptosis in mediating cyclophosphamide induced teratogenesis in vitro.
TL;DR: The results were found to be dose-dependant, and the data suggested that apoptosis is involved in mediating the teratogenicity of CP in vitro.
References
More filters
Journal ArticleDOI
The status of platinum anticancer drugs in the clinic and in clinical trials.
TL;DR: The status of platinum anticancer drugs currently approved for use, those undergoing clinical trials and those discontinued during clinical trials are updated, and the results in the context of where the field will develop over the next decade are discussed.
Journal ArticleDOI
Natural products to drugs: natural product derived compounds in clinical trials
Mark S. Butler,Mark S. Butler +1 more
TL;DR: Natural product and natural product-derived compounds that are being evaluated in clinical trials or are in registration (as at 31st December 2007) have been reviewed, as well as natural products for which clinical trials have been halted or discontinued since 2005.
Journal ArticleDOI
Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs)
John Ramage,A Ahmed,J Ardill,N.D.S. Bax,David J. Breen,Martyn Caplin,Pippa Corrie,J Davar,Albert Davies,Val Lewington,Tim Meyer,John Newell-Price,Graeme J. Poston,N. Reed,Andrea Rockall,William P. Steward,Rajesh V. Thakker,C. Toubanakis,Juan W. Valle,Caroline S. Verbeke,Ashley B. Grossman +20 more
TL;DR: These guidelines update previous guidance published in 2005 and have been revised by a group who are members of the UK and Ireland Neuroendocrine Tumour Society with endorsement from the clinical committees of the British Society of Gastroenterology and others.
Journal ArticleDOI
Cellular distribution and functions of P2 receptor subtypes in different systems.
TL;DR: This review is aimed at providing readers with a comprehensive reference article about the distribution and function of P2 receptors in all the organs, tissues, and cells in the body.
Journal ArticleDOI
Natural products: an evolving role in future drug discovery.
Bhuwan B. Mishra,Vinod K. Tiwari +1 more
TL;DR: The present review describes natural products, semi-synthetic NPs and NP-derived compounds that have undergone clinical evaluation or registration from 2005 to 2010 by disease area i.e. infectious, immunological, cardiovascular, neurological, inflammatory and related diseases and oncology.